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ABSTRACT
Introduction: The purpose of our study was to
investigate the impact of ketorolac addition to
the well-established combination of
antibiotic-steroid agent in terms of
vision-related quality of life.
Methods: Patients were randomized to: (1)
fixed combination of tobramycin
0.3%–dexamethasone 0.1%, one drop qid
(n = 68) and (2) fixed combination of
tobramycin 0.3%–dexamethasone 0.1%, one
drop qid, plus ketorolac tromethamine 0.5%,
one drop tid (n = 70). All patients completed
the VFQ-25 questionnaire to assess their
functional vision before cataract surgery and
postoperatively on days 7, 28 and 42. The
statistical analysis comprised the point-wise
comparison between the two groups at the
four time points for all sub-scales of the
VFQ-25 questionnaire, as well as the
composite score.
Results: No significant differences were noted
regarding the composite score, as well as all
subscales in all examined time points.
Conclusions: The addition of ketorolac did not
seem to offer any additional benefit in terms of
vision-related quality of life.
Keywords: Cataract; Function; Quality of life;
VFQ-25
INTRODUCTION
Cataracts are a main cause of blindness in the
world [1, 2]. Ophthalmologists have become
concerned about the visual problems caused by
cataracts in everyday life and noted that visual
impairment was not adequately measured by
visual acuity [3, 4]. In fact, visual acuity as a sole
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index may not capture all meaningful aspects of
cataract surgery-related outcomes, as it does not
take into account postoperative functional
improvement, changes in daily life activities
and satisfaction with vision [4].
Several vision-specific health-related quality
of life instruments have been used to assess
vision-related functional impairment [3]. One
such questionnaire is the National Eye Institute
Visual Function Questionnaire-25 (VFQ-25),
which was introduced by Mangione et al. to
evaluate vision-related quality of life in patients
with chronic eye diseases, including cataracts,
age-related macular degeneration, glaucoma,
diabetic retinopathy, keratoconus, CMV
retinitis or branch retinal vein occlusion [5, 6].
Indeed, the VFQ-25 assesses not only visual
function impairment, but also the impact of
ocular diseases on patients’ daily life from a
substantial number of viewpoints [7].
Our previous study has assessed the impact
of cataracts in relation to various modifiers
upon vision-related quality of life [8]; other
studies examined the outcomes of cataract
surgery, comparing VFQ scores pre- and
postoperatively, as well as investigating the
possible factors associated with the difference
in vision-related quality of life before and after
cataract surgery [3, 4, 7–10]. Nevertheless, no
attempt has been made to evaluate whether
postoperative pharmaceutical treatment may
modify vision-related quality of life in cataract
patients undergoing uneventful
phacoemulsification. In one of our previous
studies, we found that the addition of a
non-steroidal agent i.e., ketorolac, did not
seem to offer any additional benefit in terms
of inflammation-related signs (corneal edema,
redness, Tyndall reaction) [11]. In light of the
above, our study aims to investigate the impact
of ketorolac addition to the well-established
combination of antibiotic-steroid agent in
terms of vision-related quality of life. This
effort envisages to extrapolate and further
validate the results of our previous study [11].
METHODS
All participants underwent a routine
ophthalmological examination i.e.,
measurement of best-corrected visual acuity
(BCVA) by means of Snellen charts, slit lamp
examination, intraocular pressure measurement
by Goldmann applanation tonometry and
fundoscopy in addition to a complete medical
history. Patient information included age, sex,
educational and marital status, number of
offspring and siblings, alcohol consumption,
income, expenses, exercise, current smoking
and presence of diabetes mellitus. Cataract was
classified as: immature (partially opaque lens,
disc view hazy), mature (completely opaque
lens, no disc view), hypermature (liquefied
cortical matter), Morganian. Exclusion criteria
were the following: (1) history of intraocular
surgery in the operated eye, (2) any previous
episode of uveitis in the operated eye, (3) severe
systemic disease (heart failure NYHA stage III of
IV, end-stage renal failure, pulmonary failure,
patients receiving chemotherapy), (4) regular,
systemic use of steroid or non-steroidal
anti-inflammatory drugs during the last three
months, (5) uncontrolled glaucoma.
On the day of surgery, the pupil was dilated
with tropicamide 0.5% (Tropixal, Demo) and
phenylephrine hydrochloride 5%
(Phenylephrine, Cooper) drops every 10 for
30 min before surgery. Phacoemulsification
was performed using Alcon Series 20000
Legacy by the same surgeon (LP).
Patients were randomized to one of the two
postoperative treatment arms: (1) tobramycin
0.3%–dexamethasone 0.1% (TobraDex,
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Alcon), one drop four times/day (TD group,
n = 72) and (2) combination of tobramycin
0.3%–dexamethasone 0.1% (TobraDex,
Alcon), one drop four times/day, plus
ketorolac tromethamine 0.5% (Acular,
Allergan), one drop three times/day (TD-K
group, n = 73). The topical treatment was
administered for 28 days after
phacoemulsification. The study was masked to
patients, i.e., patients received unmarked
bottles so as to be unaware of which treatment
they received. Patients who needed additional
pupil devices for inadequate dilation or those
whose underwent vitrectomy due to posterior
capsule rupture (PCR) were excluded; as a result,
68 patients were ultimately included in the TD
group and 70 patients in the TD-K group, as
shown in the respective flowchart [11] (Fig. 1).
All patients completed the VFQ-25 in order
to assess their functional vision before cataract
surgery and postoperatively on day 7, 28 and
42. The VFQ-25 measures the following
vision-dependent sub-scales: general health
(GH), general vision (GV), ocular pain (OP),
near activities (NA), distance activities (DA),
social functioning (VSSF), mental health
(VSMH), role difficulties (VSRD), dependency
(VSD), driving (D), colour vision (CV) and
peripheral vision (PV). The subscales score
ranges from 0 to 100. A score of 0 indicates
the worst possible score and a score of 100 the
best possible score. We have used the official
VFQ-25 Greek translation by the Laboratory of
Experimental Ophthalmology of Aristotle
University, Thessaloniki, Greece, 2000 [12].
This study is in accordance with the
Declaration of Helsinki and has been approved
by the local Institutional Review Board. Written
informed consent was obtained from all
patients. The authors declare no conflict of
interest.
Statistical Analysis
The statistical analysis comprised the point-wise
comparison between the two groups (TD vs.
Fig. 1 Flowchart, showing the study design and randomization
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TD-K group) at the four time points (baseline,
day 7, day 28 and day 42) for all sub-scales of
the VFQ-25 questionnaire, as well as the
composite score. Student’s t test was
appropriately implemented when subscales
were normally distributed (GH, GV, OP). On
the other hand, in case of significant deviation
from normality (NA, DA, VSSF, VSMH, VSRD,
VSD, D, PV, as well as the composite score)
Mann–Whitney–Wilcoxon test for independent
samples (MWW for brevity) was performed. The
deviation from normality was assessed by
means of the Shapiro–Wilk test. Given that
four comparisons took place for each
outcome-subscale (baseline, day 7, day 28 and
day 42), the Bonferroni correction for multiple
comparisons was adopted; as a result, the
threshold of statistical significance for p was
set at 0.05/4 = 0.0125.
For the post hoc additional, secondary
comparison aiming to examine whether the
overall condition of patients improved after the
completion of the follow-up period, Wilcoxon
matched-pairs signed-rank test was performed
on the VFQ-25 composite score, separately for
each group. Statistical analysis was performed
with STATA 11.1 statistical software (StataCorp,
College Station, TX, USA).
RESULTS
The study design, as well as the randomization
of patients to the two groups, is depicted in the
respective flow chart (Fig. 1), which has been
presented in our previous study [11]. Patients’
data are summarized in Table 1 [11].
The VFQ-25 sub-scales scores of the
participants are shown in Table 2, by study
group for all time points. No significant
differences were noted regarding the
composite score in all examined time points
(90.8 ± 2.1 vs. 90.8 ± 1.7, p = 0.833 on day 7;
91.0 ± 2.2 vs. 90.8 ± 1.7, p = 0.360 on day 28;
90.8 ± 2.3 vs. 90.7 ± 1.8, p = 0.467 on day 42).
Accordingly, the lack of significant differences
between the TD and TD-K group pertained to all
subscales. A borderline trend that may merit
highlighting pertains to the relatively higher
values of NA subscale in TD-K group compared
to TD group, which were consistently observed
in all three time points (p = 0.014 on day 7,
p = 0.025 on day 28, p = 0.024 on day 42)
(Fig. 2).
She post hoc additional, secondary
comparison aiming to examine whether the
overall condition of patients improved after the




Continuous variables Mean ± SD Mean ± SD
Age (years) 74.0 ± 7.6 74.3 ± 7.3
Categorical and ordinal
variables
N (%) N (%)
Male sex 40 (58.9) 43 (61.4)
Current smoking status
(yes)
11 (16.2) 8 (11.4)
Hypertension (yes) 62 (91.2) 61 (87.1)
Diabetes mellitus (yes) 7 (10.3) 6 (8.6)
Diabetic retinopathy (yes) 2 (2.9) 1 (1.4)
Cataract stage
Immature 38 (55.9) 32 (45.7)
Mature 27 (39.7) 36 (51.4)
Hypermature 1 (1.5) 2 (2.9)
Morgagnian 2 (2.9) 0 (0.0)
Glaucoma (yes) 5 (7.4) 7 (10.0)
Pseudoexfoliation (yes) 13 (19.1) 12 (17.1)
Age-related macular
degeneration (yes)

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































completion of the follow-up period pointed to
significant improvement in VFQ-25 composite
score in both groups (p\0.0001, Wilcoxon
matched-pairs signed-rank test for each group).
In addition, the BCVA (logMAR) did not differ
between the two groups at any time point (for TD
andTD-K respectively: 0.22± 0.11 vs. 0.22± 0.10
onday 7, p = 0.955,MWW;0.08± 0.09 vs. 0.06±
0.07 on day 14, p = 0.425, MWW; 0.04± 0.07 vs.
0.04± 0.06 on day 21, p = 0.887, MWW; 0.03±
0.06 vs. 0.03± 0.05 on day 28, p = 0.373, and
0.03± 002 vs. 0.03± 0.01 on day 42, p = 0.198).
Worthyofnote, therewas a significant correlation
between BCVA and VFQ-25 at all time-points in
bothgroups (Spearman’s rho = -0.085onday42,
p\0.001).
DISCUSSION
The principal message of this study is that the
addition of a non-steroidal anti-inflammatory
agent (ketorolac) after uneventful
phacoemulsification surgery did not seem to
offer any additional benefit in terms of quality
of life when compared to the antibiotic/steroid
group.
The rationale for the addition of ketorolac
after phacoemulsification cataract surgery lies
to the prevention of cystoid macular edema
(CME) [11]. Advances in cataract surgery have
taken place, including the minimally invasive
cataract surgery, as well as the femtosecond
laser assisted cataract surgery (FLACS), which
led to reduction of postoperative inflammation
[13]. Therefore, one could hypothesize that
there is no need for the addition of ketorolac
after uneventful phacoemulsification.
Our study shows that phacoemulsification
with IOL implantation is an effective and safe
method for improving vision-related quality
of life, as both groups presented
improvement in composite score
postoperatively in comparison to
preoperative scores. This is in line with
previous studies, which also found a
significant difference in vision-related
Fig. 2 VFQ-25 composite score values (mean ± SD) in the two study groups
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quality of life between pre- and
post-operative measurements [3, 4, 7–10].
Previous studies also suggest that visual
acuity is not a good predictor of patients’
satisfaction after cataract surgery and that
vision-related quality of life questionnaires
are more accurate in measuring patients’
postoperative function [3, 4, 7–10].
According to one cross-sectional study
conducted by our team on 220 patients who
were eligible for phacoemulsification cataract
surgery, baseline vision-related quality of life is
affected by inherent sociodemographic and
lifestyle parameters, such as gender,
educational level, marital status, current
working status and exercise [8]. In the present
study, as the two groups were randomized, the
various modifiers did not differ significantly. As
a result, although potential risk factors may
confer meaningful discrepancies in
vision-related quality of life in cataract
patients, in our current study, they seemed
not to have any effect depending on the
postoperative treatment regimen.
Another interesting finding of the present
study was the borderline trend for relatively
higher values of NA subscale in TD-K group
compared to TD group, which were consistently
observed in all three time points. Future studies
may focus on the examination of the possible
pathophysiological mechanism for this trend,
which remains elusive.
Nevertheless, some limitations of the study
should be declared. Firstly, it should be noted
that sample size calculation was not performed.
Furthermore, the randomization procedure was
based on ‘‘random numbers’’ and did not
include the cataract stage or the visual needs
of patients, although the two groups seemed to
have similar characteristics. Moreover, other
treatment regimens would be desirable to be
evaluated, as the results of the study may be
influenced by regimens including other
treatment combinations.
CONCLUSIONS
In conclusion, this is the first study evaluating
the impact of ketorolac in quality of life after
uneventful phacoemulsification, suggesting
that the addition of a non-steroidal
anti-inflammatory agent (ketorolac) after
uneventful phacoemulsification surgery did
not seem to offer any additional benefit in
terms of quality of life when compared to the
antibiotic/steroid group, in line with our
previous study, according to which the
addition of ketorolac was not associated with
additional benefit regarding clinical signs and
recovery in BCVA.
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